Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus

Hepatology

Volumn 61, Issue 2, 2015, Pages 460-470

  Hoffmann, Franziska S ^a   Schmidt, Andreas ^a   Dittmann Chevillotte, Meike ^b   Wisskirchen, Christian ^a   Hellmuth, Johannes ^a   Willms, Simone ^a   Gilmore, Rachel H ^b   Glas, Jürgen ^c,d   Folwaczny, Matthias ^c   Müller, Tobias ^e   Berg, Thomas ^f   Spengler, Ulrich ^g   Fitzmaurice, Karen ^h   Kelleher, Dermot ^h   Reisch, Nicole ^c   Rice, Charles M ^b   Endres, Stefan ^a   Rothenfusser, Simon ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b ROCKEFELLER UNIVERSITY   (United States)

^c UNIVERSITY OF MUNICH   (Germany)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^g UNIVERSITY OF BONN   (Germany)

^h ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

HISTIDINE; THREONINE; DEAD BOX PROTEIN; IFIH1 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; EUROPEAN; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA DIFFERENTIATION ASSOCIATED GENE 5; PERSISTENT INFECTION; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL CLEARANCE; VIRUS REPLICATION; CASE CONTROL STUDY; CHRONIC HEPATITIS C; COMPARATIVE STUDY; GENETICS; HEK293 CELL LINE; HEPACIVIRUS; HOST PATHOGEN INTERACTION; PHYSIOLOGY; REMISSION; VIROLOGY;

CASE-CONTROL STUDIES; DEAD-BOX RNA HELICASES; FEMALE; HEK293 CELLS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; MALE; POLYMORPHISM, GENETIC; REMISSION, SPONTANEOUS;

EID: 84921532403     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27344     Document Type: Article

References (44)

1. Romero-Gomez M, Eslam M, Ruiz A, Maraver M. Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. Liver Int 2011;31:443-460.
2. Selvarajah S, Tobler LH, Simmons G, Busch MP. Host genetic basis for hepatitis C virus clearance: a role for blood collection centers. Curr Opin Hematol 2010;17:550-557.
3. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
4. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-1104.
5. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-1109.
6. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801.
7. Metz P, Reuter A, Bender S, Bartenschlager R. Interferon-stimulated genes and their role in controlling hepatitis C virus. J Hepatol 2013;59:1331-1341.
8. Schoggins JW, Rice CM. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol 2012;1:519-525.
9. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140:805-820.
10. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006;314:994-997.
11. Pichlmair A, Schulz O, Tan CP, Rehwinkel J, Kato H, Takeuchi O, et al. Activation of MDA5 requires higher-order RNA structures generated during virus infection. J Virol 2009;83:10761-10769.
12. Schmidt A, Schwerd T, Hamm W, Hellmuth JC, Cui S, Wenzel M, et al. 5'-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proc Natl Acad Sci U S A 2009;106:12067-12072.
13. Loo YM, Gale M Jr. Immune signaling by RIG-I-like receptors. Immunity 2011;34:680-692.
14. Schmidt A, Endres S, Rothenfusser S. Pattern recognition of viral nucleic acids by RIG-I-like helicases. J Mol Med 2011;89:5-12.
15. Horner SM, Gale M Jr. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med 2013;19:879-888.
16. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005;437:1167-1172.
17. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011;472:481-485.
18. Sumpter R Jr, Loo YM, Foy E, Li K, Yoneyama M, Fujita T, et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 2005;79:2689-2699.
19. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-1233.
20. Horwitz JA, Dorner M, Friling T, Donovan BM, Vogt A, Loureiro J, et al. Expression of heterologous proteins flanked by NS3-4A cleavage sites within the hepatitis C virus polyprotein. Virology 2013;439:23-33.
21. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-626.
22. Liu S, Wang H, Jin Y, Podolsky R, Reddy MV, Pedersen J, et al. IFIH1 polymorphisms are significantly associated with type 1 diabetes and IFIH1 gene expression in peripheral blood mononuclear cells. Hum Mol Genet 2009;18:358-365.
23. Smyth DJ, Cooper JD, Bailey R, Field S, Burren O, Smink LJ, et al. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet 2006;38:617-619.
24. Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 2009;324:387-389.
25. Shigemoto T, Kageyama M, Hirai R, Zheng J, Yoneyama M, Fujita T. Identification of loss of function mutations in human genes encoding RIG-I and MDA5: implications for resistance to type I diabetes. J Biol Chem 2009;284:13348-13354.
26. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci U S A 2005;102:17717-17722.
27. Fredericksen BL, Keller BC, Fornek J, Katze MG, Gale M Jr. Establishment and maintenance of the innate antiviral response to West Nile Virus involves both RIG-I and MDA5 signaling through IPS-1. J Virol 2008;82:609-616.
28. Li Q, Brass AL, Ng A, Hu Z, Xavier RJ, Liang TJ, et al. A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci U S A 2009;106:16410-16415.
29. Israelow B, Narbus CM, Sourisseau M, Evans MJ. HepG2 cells mount an effective antiviral interferon-lambda based innate immune response to hepatitis C virus infection. Hepatology 2014 [Epub ahead of print].
30. Andrus L, Marukian S, Jones CT, Catanese MT, Sheahan TP, Schoggins JW, et al. Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells. Hepatology 2011;54:1901-1912.
31. Motz C, Schuhmann KM, Kirchhofer A, Moldt M, Witte G, Conzelmann KK, et al. Paramyxovirus V proteins disrupt the fold of the RNA sensor MDA5 to inhibit antiviral signaling. Science 2013;339:690-693.
32. Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, Flavell RA, et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A 2006;103:8459-8464.
33. Kato H, Takeuchi O, Mikamo-Satoh E, Hirai R, Kawai T, Matsushita K, et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 2008;205:1601-1610.
34. Triantafilou K, Vakakis E, Kar S, Richer E, Evans GL, Triantafilou M. Visualisation of direct interaction of MDA5 and the dsRNA replicative intermediate form of positive strand RNA viruses. J Cell Sci 2012;125:4761-4769.
35. Zouk H, Marchand L, Polychronakos C. Study of transcriptional effects in Cis at the IFIH1 locus. PLoS One 2010;5:e11564.
36. Kowalinski E, Lunardi T, McCarthy AA, Louber J, Brunel J, Grigorov B, et al. Structural basis for the activation of innate immune pattern-recognition receptor RIG-I by viral RNA. Cell 2011;147:423-435.
37. Luo D, Ding SC, Vela A, Kohlway A, Lindenbach BD, Pyle AM. Structural insights into RNA recognition by RIG-I. Cell 2011;147:409-422.
38. Jiang F, Ramanathan A, Miller MT, Tang GQ, Gale M Jr, Patel SS, et al. Structural basis of RNA recognition and activation by innate immune receptor RIG-I. Nature 2011;479:423-427.
39. Wu B, Peisley A, Richards C, Yao H, Zeng X, Lin C, et al. Structural basis for dsRNA recognition, filament formation, and antiviral signal activation by MDA5. Cell 2013;152:276-289.
40. Peisley A, Lin C, Wu B, Orme-Johnson M, Liu M, Walz T, et al. Cooperative assembly and dynamic disassembly of MDA5 filaments for viral dsRNA recognition. Proc Natl Acad Sci U S A 2011;108:21010-21015.
41. Berke IC, Yu X, Modis Y, Egelman EH. MDA5 assembles into a polar helical filament on dsRNA. Proc Natl Acad Sci U S A 2012;109:18437-18441.
42. Tauriainen S, Oikarinen S, Oikarinen M, Hyoty H. Enteroviruses in the pathogenesis of type 1 diabetes. Semin Immunopathol 2011;33:45-55.
43. Rice GI, Del Toro Duany Y, Jenkinson EM, Forte GM, Anderson BH, Ariaudo G, et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat Genet 2014;46:503-509.
44. Cen H, Wang W, Leng RX, Wang TY, Pan HF, Fan YG, et al. Association of IFIH1 rs1990760 polymorphism with susceptibility to autoimmune diseases: a meta-analysis. Autoimmunity 2013;46:455-462.